Ion Beam Applications Company Description
Ion Beam Applications SA develops, manufactures, and supports medical devices and software solutions for cancer treatments in Belgium, the United States, and internationally.
The company operates through Proton Therapy and Other Accelerators, and Dosimetry segments. The Proton Therapy and Other Accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems.
This segment also offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of positron emission tomography or SPECT radioisotopes, as well as a line of industrial accelerators for sterilization and ionization.
The Dosimetry segment provides solutions and services that enhances efficiency and minimizes errors in radiation therapy and medical imaging quality assurance and calibration procedures.
The company has strategic research and development partnership with SCK CEN (Belgian nuclear research center) to enable the production of Actinimum-225 (225Ac), a novel radioisotope for the treatment of cancer; and an agreement with University of Pennsylvania for research in ConformalFLASH.
It also has a research partnership with Particle Therapy Interuniversity Center Leuven for the development of ConformalFLASH1.
Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.
![Ion Beam Applications logo](https://img.stockanalysis.com/logos1/BR/IBAB.png)
Country | Belgium |
Founded | 1986 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 2,145 |
CEO | Olivier Legrain |
Contact Details
Address: 3, Chemin du Cyclotron Louvain-la-Neuve, 1348 Belgium | |
Phone | 32 1 047 58 11 |
Website | iba-worldwide.com |
Stock Details
Ticker Symbol | IBAB |
Exchange | Euronext Brussels |
Fiscal Year | October - September |
Reporting Currency | EUR |
ISIN Number | BE0003766806 |
SIC Code | 3845 |
Key Executives
Name | Position |
---|---|
Henri de Romree | Deputy Chief Executive Officer |
Olivier Legrain | Chief Executive Officer, MD and Executive Director |
Pierre Mottet | Chairman of The Board |
Yves Jongen | Founder, Chief Research Officer, MD and Executive Director |
Soumya Chandramouli | Chief Financial Officer |
Marc Van der Burght | Chief Operation Officer |
Olivier Lechien | Corporate Communication Director |
Thomas Canon | Sustainability Program Director |
Bruno Scutnaire | President of IBA RadioPharma Solutions |